When a Brand Is Discontinued: Keeping a Hospital Formulary Line Supplied

The email usually comes from the UK supplier rather than from a regulator: the brand on your formulary is being discontinued, the final batch has been made, and remaining packs will be supplied while they last. For a hospital pharmacy or procurement lead outside the UK, that notice carries an extra layer of difficulty. The product is probably registered in your market under that brand name, the tender was awarded on that brand, and the prescribers know it by name. Replacing it is not a line edit. It is a regulatory, clinical and procurement exercise with a clock already running, and this guide is for the person who has just received the notice.

For transparency: Euro Biom Ltd is a UK MHRA-licensed pharmaceutical wholesale exporter, WDA(H) 59239, supplying only UK-licensed, MHRA-authorised finished medicines. We cannot bring back a brand its manufacturer has withdrawn and we do not supply unlicensed medicines. What we can do is find the UK-licensed path, and that is the frame for everything below.

The Short Answer

• Act on the day the notice arrives. Quantify months of cover from your own remaining quantity and what the supplier can still allocate.
• Secure what remains of the brand, but only as much as will be used before expiry.
• Look first for a UK-licensed product of the same INN, strength and form: a generic, another brand or a pack under a UK parallel import licence.
• Only then consider a different strength or form, and after that a therapeutic alternative, both with the prescriber's written agreement.
• If no registered alternative exists in your market, the route is your own named-patient or import-permit mechanism for a UK-licensed product, not an unlicensed import of the old brand.
• Document every step as if an inspector or donor auditor will read it.

How a UK Discontinuation Is Announced

There is no single public register of UK discontinuations that an overseas buyer can subscribe to. Information flows through three channels, and only one of them reliably reaches you.

The first is the regulator. MHRA's sunset clause guidance states that authorisation owners should notify MHRA if a product is temporarily or permanently taken off the market, and that an authorisation is no longer valid for a product that has not been placed on the market for three consecutive years. That notification updates MHRA's records; it is not a customer-facing alert.

The second is the Department of Health and Social Care. Regulations 28 and 29 of the Health Service Products (Provision and Disclosure of Information) Regulations 2018, as referenced in the DHSC's published reporting requirements, require marketing authorisation holders to report shortages and discontinuations to the DHSC, which asks for reports through its online portal. The notice period that applies to a planned discontinuation is set by the regulations themselves, so check the current text before quoting a figure. The DHSC uses that information to issue Medicine Supply Notifications and to populate the Medicines Supply Tool hosted by the Specialist Pharmacy Service. Both are NHS-facing instruments, cascaded to NHS providers and accessed through registration, not designed for a hospital in Riyadh, Lagos or Johannesburg.

The third channel is the one that matters to you. In practice, manufacturers usually alert their UK wholesale customers when a product is being withdrawn, though no public rule guarantees that the alert reaches an overseas buyer. The manufacturer tells its UK wholesale customers, and the wholesale exporter tells you. Your early warning therefore depends on your UK supplier passing notices on promptly and in full, a reasonable clause for a supply agreement.

Four events that look the same from your desk

The fourth case is the easiest to solve and the easiest to misdiagnose. If the product is still UK-licensed and still manufactured, you have a sourcing problem, not a discontinuation, and our hard-to-source medicines page describes how we approach lines that have dropped out of routine channels.

How to Read a Discontinuation Notice

Discontinuation notices are written for the UK domestic market and often omit what an exporter's customer needs. Read the notice for six things, and ask for whichever are missing.

1. Last date of manufacture and last date of supply. These can be months apart. The supply end date is your planning anchor.
2. Remaining expiry on the final batches. A run-down batch with ten months of shelf life is useful for a bridging order and useless for a twelve-month tender commitment.
3. Scope. Is it one strength, one pack size, one form, or the whole brand? Is it UK-only, or global? A UK-only withdrawal may mean the brand continues elsewhere, but as the next section explains, that version is not something a UK wholesale exporter can supply.
4. Licence status. Is the marketing authorisation being cancelled, or is the product simply no longer marketed? In the second case the licence could be revived or transferred, which occasionally happens for hospital products.
5. The manufacturer's stated alternative. Many notices name the product the manufacturer expects customers to move to. Treat it as a candidate, not a decision.
6. Allocation. Run-down batches are typically rationed. Ask what your supplier can allocate to you, and by when you must confirm.

One more check belongs in the first week. A UK discontinuation often tightens supply of the remaining alternatives, and products in short supply can be added to the DHSC and MHRA list of medicines that cannot be parallel exported from the UK. Before building a plan around a UK-licensed alternative, confirm it is not on that list. Our article on UK medicine export restrictions in 2026 explains how the list works.

The Realistic Options, in Order

The sequence below runs from least to most disruptive. Each step down adds regulatory and clinical work in the destination market, so stop at the first that gives a durable supply.

What is not on the list

Importing the old brand from a third country once UK supply has gone is not an option through a UK wholesale exporter. A product with no valid UK marketing authorisation is, in UK terms, an unlicensed medicine, and Euro Biom does not supply unlicensed medicines or specials. The job is to find the UK-licensed path, and if there is none, to say so plainly.

One note on option 2. The Specialist Pharmacy Service confirms that parallel imports are licensed medicines in the UK and that, since 1 January 2025, all carry a UK-wide PLPI licence from MHRA, but also that they do not have a UK Summary of Product Characteristics. Your committee will compare the imported pack against the UK reference product's SmPC, and your regulator may treat the different licence holder as a variation. Neither is a barrier; both need anticipating.

What Changes in the Destination Market When the Brand Changes

From the UK side, moving between UK-licensed products of the same INN is routine. From your side, six things change at once.

Registration

Many regulators in the GCC and Africa register a product by brand, manufacturer and site rather than by INN, so check your own regulator's rule. A change of manufacturer or licence holder is at minimum a variation and often a new registration, with its own fee and review period. If the replacement is not registered in your market at all, you are in option 5, and the choice between a one-off import and full registration is covered in our article on named-patient import versus local registration.

Tender and contract

If the line was awarded on a brand name, the contract may not allow substitution without a formal amendment or a re-tender. The safe assumption is that the contracting authority must approve the change in writing before the first replacement consignment ships.

Formulary committee approval

A pharmacy and therapeutics committee will want the comparison done properly: SmPC against SmPC, excipients against excipients, pack against pack. Supplying that evidence early shortens the approval cycle more than any amount of chasing.

Label and leaflet

The replacement pack is a UK pack: English-language labelling, the UK licence number and, for packs released since 1 January 2025, the "UK only" marking on the outer carton. Whether local over-labelling or a translated leaflet is required is a destination-regulator question. Build it into the timeline.

Excipients and allergy

Two products with identical active ingredient, strength and form can differ in excipients: lactose, gluten-containing starch, colourants, sulphites, alcohol in oral liquids, gelatin in capsules. For patients with documented allergies, and for institutions applying halal or dietary criteria to gelatin sources, the excipient comparison is a clinical and sometimes a cultural requirement.

Bioequivalence and modified release

For most medicines, a UK-licensed generic is interchangeable with the brand. For a defined group of narrow-therapeutic-index and modified-release products, the switch needs clinical oversight, which is the subject of the next section.

Narrow-Therapeutic-Index and Brand-Sensitive Medicines

The clearest regulatory statement on this is the MHRA's Drug Safety Update of November 2017 on switching between different manufacturers' products for antiepileptic drugs. It sorts the medicines into three categories. Category 1, which the MHRA says should be maintained on a specific manufacturer's product, contains carbamazepine, phenobarbital, phenytoin and primidone. Category 2 products, including valproate and lamotrigine, are judged case by case on factors such as seizure frequency and treatment history. For category 3, the MHRA considers the potential for clinically relevant differences to be extremely low.

Phenobarbital in that list is a controlled drug, outside Euro Biom's scope; it appears here only because it is in the MHRA's category, not because we supply it.

A discontinuation is the one situation in which a category 1 switch cannot be avoided. The Specialist Pharmacy Service's guidance on switching anti-seizure medicines treats manufacturer shortage as an extenuating circumstance for category 1 products, and makes the point that another manufacturer's version of the same medicine is preferable to a missed dose, because small differences in bioavailability carry far less risk than an interruption in treatment. It also notes more concern about switching modified-release products.

For an overseas hospital, that means three rules. The switch is prescriber-led, product by product. Patients on the affected medicine are identified and monitored through the changeover, which is easier when the bridging supply gives you a planned switch date. And the replacement is chosen once, for the whole cohort, so patients are not moved between manufacturers repeatedly. Our CNS and neurology page lists the UK-licensed products we can quote in this area, and our oncology page covers another class where brand changes are watched closely by clinicians.

A Timed Plan from Notice to Replacement

Any notice period in the UK regulations is the manufacturer's duty to the DHSC, not a promise to you. By the time the information has travelled through a wholesaler to an overseas customer, the usable window is often shorter. The plan below assumes roughly six months; with three, run the first four stages in parallel.

The hardest stage is week 2. Until you know each candidate's registration status in your market, you cannot size the bridging order or choose the regulatory route. Our import requirements checker gives a first view of the documents each regulator typically expects for a UK-licensed product, useful for scoping the application early.

Securing a Bridging Supply

A bridging supply covers the gap between the last dispensed pack of the old brand and the first lawful dispensing of the replacement. Size it from three numbers, not from instinct.

• Cover to the switch date. Monthly consumption multiplied by the months until the replacement is approved and on site, plus a margin for slippage.
• Expiry fit. Only the quantity that will be used before the run-down batch expires. Over-ordering a discontinued brand produces write-offs and, in some markets, a disposal paperwork trail worse than the shortage.
• Allocation reality. The quantity the UK supplier can confirm against named batches. A wholesaler's position depends on what the manufacturer allocates to it, so ask for batch and expiry confirmation at quotation, not a blanket assurance.

Where the replacement is not registered and you are importing under your own named-patient or permit route, align the permit validity with the consignment. SAHPRA's Section 21 FAQ, for example, states that the prescribing medical practitioner must apply, that the Section 21 Unit aims to decide within three working days of receipt through its online system, and that a new application is needed once six months have elapsed since approval. A bridging order that lands after the permit has lapsed is stuck in customs. Our named-patient supply page sets out what Euro Biom provides on the UK side of that route, and our South Africa and Saudi Arabia pages describe the local frameworks buyers in those markets work within.

Temperature matters too. If the old brand and the replacement have different storage conditions, for instance one at 2-8°C and one at room temperature, the change must reach the ward refrigerators and the stock system before the first replacement consignment arrives. For urgent gaps where the brand has run out before the replacement is approved, our drug shortage supply page explains how we handle a time-critical line, and our guide to drug shortages for hospitals covers the options when a shortage, rather than a discontinuation, is the cause.

Documenting the Substitution

A substitution that is not documented looks, to an inspector, like an uncontrolled change. The file need not be long, but it must be complete. Keep the following together, in the order the decisions were made.

1. The supplier's discontinuation notice, with the date received.
2. The consumption and cover calculation, and the reserved quantity of the old brand with batch numbers and expiry dates.
3. The candidate list from the UK supplier, with manufacturer, licence holder and UK licence number for each.
4. The export-restriction check for each candidate, dated.
5. The equivalence assessment: INN, strength, form, excipients, storage conditions, and a side-by-side of the relevant SmPC sections. For a parallel import, the UK reference product's SmPC and the importer's licence details.
6. The prescriber's agreement and the committee minute, including any dose-conversion instruction.
7. The destination regulator's variation approval, registration certificate, or named-patient or import-permit authorisation, with validity dates.
8. The tender or contract amendment.
9. The Certificate of Pharmaceutical Product and other export documents for the replacement, as described in our import documentation guide.
10. Batch and expiry confirmation for the first replacement consignment, with receiving and quarantine records.
11. The stock-system, label and ward-communication changes, and the switch date.
12. Any patient-level monitoring record for brand-sensitive medicines.

Items 5 and 6 are the ones worth checking first, because they show why the replacement was judged suitable.

What a Wholesaler Cannot Do

• Make the brand reappear. Once the marketing authorisation holder has stopped supply, no wholesaler can manufacture or commission the product.
• Supply an unlicensed version. Euro Biom supplies only UK-licensed, MHRA-authorised finished medicines. We do not supply unlicensed medicines or specials, and our scope does not cover vaccines, biologics, biosimilars, insulin, blood or plasma products or controlled drugs.
• Export a restricted line. Medicines on the DHSC and MHRA parallel export restriction list cannot be exported from the UK by any wholesaler or manufacturer.
• Hold your registration or your permit. The variation, the registration and the import authorisation are the buyer's or the local agent's, never the UK exporter's.
• Override allocation. A wholesaler can confirm batches it has been allocated, not a quantity the manufacturer has not released.
• Make clinical decisions. The choice between a generic, a different strength or a different molecule belongs to your prescribers and your committee.

Where Euro Biom Fits

When a customer sends us a discontinuation notice, the work on our side is specific. We identify the UK-licensed products of the same INN, strength and form that we can trace in the UK supply chain, including parallel-imported packs under a PLPI, with the manufacturer, licence holder and licence number for each, and check each against the UK export restriction list. We quote line by line, confirming batch and expiry so that your bridging order is sized against real dates. We provide the product information available for each candidate (the SmPC where one exists, the patient leaflet and pack details) for your committee and regulator, and the export documents for the replacement, dispatched via London Heathrow under GDP. Where the replacement is not registered in your market, we support your own import-permit or named-patient application with the UK-side documents it requires.

What we do not do is pretend the gap can be closed in every case. Some discontinued products have no UK-licensed equivalent in the same form, and the honest answer is to say so early, so that your clinicians can move to option 3 or 4 with time in hand. Distributors can open a pharmaceutical trade account; for a single notice, the enquiry form is enough.